Biotech Archives - Page 69 of 795

2 minute read

Caribou Biosciences Announces Oral Presentation On In Vivo Cas12a chRDNA Genome Editing At The 27th Annual Meeting Of ASGCT

April 15, 9:15 AM

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo

CRBU

2 minute read

Roche’s Lymphoma Drug With Chemo Extends Survival In Pretreated Patients

By Vandana Singh

April 15, 8:56 AM

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.

HOOK

2 minute read

NRx Pharmaceuticals Announces Development Of New, Proprietary Formulation Of HTX-100 (IV Ketamine)

By Benzinga Newsdesk

April 15, 8:34 AM

Formulation based on prior patents by NRx founderAchieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administrationCompany expects Composition of Matter patent

NRXP

2 minute read

UroGen Announces FDA Acceptance Of IND Application For UGN-103, A Next Generation Mitomycin-Based Formulation For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

By Benzinga Newsdesk

April 15, 8:11 AM

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process,

URGN

1 minute read

Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET

By Benzinga Newsdesk

April 12, 4:23 PM

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link belowNOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that

RARE

2 minute read

Small-Cap Cancer Drug Developer Agenus’ Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

By Vandana Singh

April 12, 2:18 PM

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

AGEN

2 minute read

Penny Stock PaxMedica’s African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

By Vandana Singh

April 12, 12:02 PM

PaxMedica achieves pivotal milestone with completion of three registration/validation batches for PAX-101, an IV suramin formulation, advancing towards FDA submission in Q4 2024. Potential breakthrough treatment for Stage 1 HAT, a fatal tropical disease.

PXMD

2 minute read

Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy

By Vandana Singh

April 12, 11:54 AM

U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority, dismissing Lilly's state law maneuvering.

LLY

2 minute read

Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats

By Vandana Singh

April 12, 11:30 AM

Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safety record, emphasizing positive outcomes for millions of treated animals.

ZTS

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet

By Chris Katje

April 12, 11:26 AM

The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week's stocks to watch.

CEG